Cancer feature: cnaPANCAN62

AP006621.5 AP2A2 ASCL2 BRSK2 C11orf21 C11orf35 C11orf89 CARS CD151 CD81 CDHR5 CDKN1C CEND1 CHID1 CTSD DEAF1 DRD4 DUSP8 EFCAB4A EPS8L2 HRAS IFITM10 IGF2 INS INS-IGF2 IRF7 KCNQ1 KRTAP5-1 KRTAP5-2 KRTAP5-3 KRTAP5-4 KRTAP5-5 KRTAP5-6 LRRC56 LSP1 MOB2 MRPL23 MUC2 MUC5AC MUC5B MUC6 NAP1L4 PDDC1 PHLDA2 PHRF1 PIDD PNPLA2 POLR2L PTDSS2 RASSF7 RNH1 RP11-295K3.1 RPLP2 SCT SLC22A18 SLC22A18AS SLC25A22 SYT8 TALDO1 TH TMEM80 TNNI2 TNNT3 TOLLIP TRPM5 TSPAN32 TSPAN4 TSSC4

Known Driver Genes: HRAS

Copy number alternation: loss

Entospletinib

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer